TDMS Study 88124-04 Pathology Tables
NTP STATISTICAL ANALYSIS OF PRIMARY TUMORS REPORT: PEIRPT08
LAB: Battelle Northwest INDIUM PHOSPHIDE DATE: 02/24/00
EXPERIMENT: 88124 TEST: 04 TIME: 08:08:20
TEST TYPE: CHRONIC CAGES FROM 0000 TO LAST CAGE PAGE: 1
CONT: NO1-ES-25335 ROUTE: RESPIRATORY EXPOSURE WHOLE BODY NTP C#: C88124
PATHOLOGIST: MILLER, R. CAS: 22398-80-7
------------------------------------------------------------------------------------------------------------------------------------
FINAL#2, 2 YEAR CHRONIC MICE
REASONS FOR REMOVAL: 25022 Accidently Killed
25019 Moribund Sacrifice
25020 Natural Death
25021 Terminal Sacrifice
REMOVAL DATE RANGE: ALL
TREATMENT GROUPS: INCLUDE ALL
NTP STATISTICAL ANALYSIS OF PRIMARY TUMORS REPORT: PEIRPT08
LAB: Battelle Northwest INDIUM PHOSPHIDE DATE: 02/24/00
EXPERIMENT: 88124 TEST: 04 TIME: 08:08:20
TEST TYPE: CHRONIC CAGES FROM 0000 TO LAST CAGE
CONT: NO1-ES-25335 ROUTE: RESPIRATORY EXPOSURE WHOLE BODY NTP C#: C88124
PATHOLOGIST: MILLER, R. CAS: 22398-80-7
Mice(B6C3F1)
-----------------------------
FOR ALL DOSES THE TUMOR RATES IN THE FOLLOWING TISSUES/ORGANS ARE
BASED ON NUMBER OF TISSUES EXAMINED. IN OTHER TISSUES/ORGANS RATES
ARE BASED ON THE NUMBER OF ANIMALS NECROPSIED.
---------------
Adrenal Cortex
Adrenal Medulla
Bone Marrow
Brain
Islets, Pancreatic
Liver
Lung
Ovary
Pituitary Gland
Spleen
Testes
Thyroid Gland
NTP STATISTICAL ANALYSIS OF PRIMARY TUMORS REPORT: PEIRPT08
LAB: Battelle Northwest INDIUM PHOSPHIDE DATE: 02/24/00
EXPERIMENT: 88124 TEST: 04 TIME: 08:08:20
TEST TYPE: CHRONIC CAGES FROM 0000 TO LAST CAGE
CONT: NO1-ES-25335 ROUTE: RESPIRATORY EXPOSURE WHOLE BODY NTP C#: C88124
PATHOLOGIST: MILLER, R. CAS: 22398-80-7
SUMMARY OF STATISTICALLY SIGNIFICANT (P<=.05) RESULTS
IN THE ANALYSIS OF INDIUM PHOSPHIDE
===============================================================
Male Mice
------------
Organ Morphology
----- ----------
Intestine Small: Site Unspecified Carcinoma
Carcinoma or Adenoma
Islets, Pancreatic Adenoma
Liver Hepatocellular Adenoma
Hepatocellular Carcinoma
Hepatocellular Carcinoma or Hepatoblastoma
Hepatocellular Carcinoma or Hepatocellular Adenoma
Hepatocellular Carcinoma, Hepatocellular Adenoma, or Hepatoblastoma
Lung Alveolar/Bronchiolar Carcinoma
Alveolar/Bronchiolar Carcinoma or Alveolar/Bronchiolar Adenoma
All Organs Benign Tumors
Malignant Tumors
Malignant and Benign Tumors
===============================================================
Female Mice
------------
Organ Morphology
----- ----------
Liver Hepatocellular Adenoma
Hepatocellular Carcinoma
Hepatocellular Carcinoma or Hepatoblastoma
Hepatocellular Carcinoma or Hepatocellular Adenoma
Hepatocellular Carcinoma, Hepatocellular Adenoma, or Hepatoblastoma
Lung Alveolar/Bronchiolar Adenoma
Alveolar/Bronchiolar Carcinoma
Alveolar/Bronchiolar Carcinoma or Alveolar/Bronchiolar Adenoma
All Organs Malignant Lymphoma: Histiocytic, Lymphocytic, Mixed, NOS, or Undifferentiated Cell Type
Benign Tumors
Malignant Tumors
Malignant and Benign Tumors
===============================================================
Date: 02/24/00 EXPERIMENT: 88124 TEST: 04 Page 1
Statistical Analysis of Primary Tumors in Mice(B6C3F1) - INDIUM PHOSPHIDE
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.03 0.1MG/M3 0.3MG/M3 |CONTROL 0.03 0.1MG/M3 0.3MG/M3 |
| | MG/M3 STOP STOP | MG/M3 STOP STOP |
|=================================================================================================================================|
| |
|Adrenal Cortex |
| Adenoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 2/50 (4%) 0/50 (0%) 1/48 (2%) 0/50 (0%) |0/50 (0%) 0/50 (0%) 0/50 (0%) 1/50 (2%) |
|POLY-3 ADJUSTED (b)| 4.3% 0.0% 2.4% 0.0% |0.0% 0.0% 0.0% 2.6% |
|TERMINAL (d) | 2/37 (5%) 0/24 (0%) 1/29 (3%) 0/27 (0%) |0/42 (0%) 0/13 (0%) 0/33 (0%) 0/21 (0%) |
|FIRST INCIDENCE | 733 (T) --- 733 (T) --- |--- --- --- 658 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.307N P=0.338N P=0.585N P=0.310N |P=0.175 (e) (e) P=0.421 |
|POLY 3 | P=0.259N P=0.275N P=0.541N P=0.262N |P=0.198 (e) (e) P=0.460 |
|POLY 1.5 | P=0.262N P=0.261N P=0.530N P=0.252N |P=0.204 (e) (e) P=0.476 |
|POLY 6 | P=0.258N P=0.291N P=0.554N P=0.275N |P=0.190 (e) (e) P=0.439 |
|LOGISTIC REGRESSION| P=0.307N (e) P=0.585N (e) |P=0.229 (e) (e) P=0.527 |
|COCH-ARM / FISHERS | P=0.272N P=0.247N P=0.515N P=0.247N |P=0.214 (e) (e) P=0.500 |
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.03 0.1MG/M3 0.3MG/M3 |CONTROL 0.03 0.1MG/M3 0.3MG/M3 |
| | MG/M3 STOP STOP | MG/M3 STOP STOP |
|=================================================================================================================================|
| |
|Adrenal Medulla |
| Pheochromocytoma Benign |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 1/50 (2%) 1/48 (2%) 1/49 (2%) |2/49 (4%) 0/49 (0%) 2/50 (4%) 0/49 (0%) |
|POLY-3 ADJUSTED (b)| 0.0% 2.6% 2.4% 2.5% |4.3% 0.0% 4.4% 0.0% |
|TERMINAL (d) | 0/37 (0%) 0/24 (0%) 1/29 (3%) 1/27 (4%) |1/41 (2%) 0/13 (0%) 2/33 (6%) 0/21 (0%) |
|FIRST INCIDENCE | --- 730 733 (T) 733 (T) |699 --- 735 (T) --- |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.440 P=0.422 P=0.451 P=0.437 |P=0.368N P=0.480N P=0.618 P=0.378N |
|POLY 3 | P=0.447 P=0.468 P=0.477 P=0.474 |P=0.295N P=0.291N P=0.693 P=0.284N |
|POLY 1.5 | P=0.461 P=0.480 P=0.483 P=0.483 |P=0.293N P=0.264N P=0.689N P=0.264N |
|POLY 6 | P=0.427 P=0.456 P=0.469 P=0.463 |P=0.298N P=0.336N P=0.680 P=0.312N |
|LOGISTIC REGRESSION| P=0.439 P=0.438 P=0.451 P=0.437 |P=0.338N P=0.319N P=0.685 P=0.287N |
|COCH-ARM / FISHERS | P=0.480 P=0.500 P=0.490 P=0.495 |P=0.287N P=0.247N P=0.684N P=0.247N |
|=================================================================================================================================|
Date: 02/24/00 EXPERIMENT: 88124 TEST: 04 Page 2
Statistical Analysis of Primary Tumors in Mice(B6C3F1) - INDIUM PHOSPHIDE
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.03 0.1MG/M3 0.3MG/M3 |CONTROL 0.03 0.1MG/M3 0.3MG/M3 |
| | MG/M3 STOP STOP | MG/M3 STOP STOP |
|=================================================================================================================================|
| |
|Harderian Gland |
| Adenoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # |# # # # |
|----------- | | |
|OVERALL (a) | 1/50 (2%) 0/50 (0%) 2/50 (4%) 2/50 (4%) |3/50 (6%) 0/50 (0%) 2/50 (4%) 2/50 (4%) |
|POLY-3 ADJUSTED (b)| 2.2% 0.0% 4.7% 4.8% |6.4% 0.0% 4.4% 5.2% |
|TERMINAL (d) | 1/37 (3%) 0/24 (0%) 1/29 (3%) 2/27 (7%) |3/42 (7%) 0/13 (0%) 2/33 (6%) 1/21 (5%) |
|FIRST INCIDENCE | 733 (T) --- 669 733 (T) |735 (T) --- 735 (T) 512 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.218 P=0.586N P=0.423 P=0.390 |P=0.433 P=0.386N P=0.609N P=0.613 |
|POLY 3 | P=0.256 P=0.532N P=0.471 P=0.462 |P=0.557 P=0.167N P=0.510N P=0.586N |
|POLY 1.5 | P=0.262 P=0.520N P=0.483 P=0.478 |P=0.560 P=0.143N P=0.502N P=0.551N |
|POLY 6 | P=0.246 P=0.544N P=0.455 P=0.443 |P=0.553 P=0.211N P=0.525N P=0.631N |
|LOGISTIC REGRESSION| P=0.237 (e) P=0.468 P=0.390 |P=0.527 (e) P=0.609N P=0.521N |
|COCH-ARM / FISHERS | P=0.265 P=0.500N P=0.500 P=0.500 |P=0.569 P=0.121N P=0.500N P=0.500N |
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.03 0.1MG/M3 0.3MG/M3 |CONTROL 0.03 0.1MG/M3 0.3MG/M3 |
| | MG/M3 STOP STOP | MG/M3 STOP STOP |
|=================================================================================================================================|
| |
|Harderian Gland |
| Carcinoma or Adenoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # |# # # # |
|----------- | | |
|OVERALL (a) | 1/50 (2%) 1/50 (2%) 3/50 (6%) 2/50 (4%) |3/50 (6%) 0/50 (0%) 2/50 (4%) 2/50 (4%) |
|POLY-3 ADJUSTED (b)| 2.2% 2.6% 7.1% 4.8% |6.4% 0.0% 4.4% 5.2% |
|TERMINAL (d) | 1/37 (3%) 1/24 (4%) 2/29 (7%) 2/27 (7%) |3/42 (7%) 0/13 (0%) 2/33 (6%) 1/21 (5%) |
|FIRST INCIDENCE | 733 (T) 733 (T) 669 733 (T) |735 (T) --- 735 (T) 512 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.334 P=0.662 P=0.230 P=0.390 |P=0.433 P=0.386N P=0.609N P=0.613 |
|POLY 3 | P=0.374 P=0.723 P=0.275 P=0.462 |P=0.557 P=0.167N P=0.510N P=0.586N |
|POLY 1.5 | P=0.386 P=0.737 P=0.288 P=0.478 |P=0.560 P=0.143N P=0.502N P=0.551N |
|POLY 6 | P=0.354 P=0.708 P=0.261 P=0.443 |P=0.553 P=0.211N P=0.525N P=0.631N |
|LOGISTIC REGRESSION| P=0.354 P=0.662 P=0.260 P=0.390 |P=0.527 (e) P=0.609N P=0.521N |
|COCH-ARM / FISHERS | P=0.399 P=0.753N P=0.309 P=0.500 |P=0.569 P=0.121N P=0.500N P=0.500N |
|=================================================================================================================================|
Date: 02/24/00 EXPERIMENT: 88124 TEST: 04 Page 3
Statistical Analysis of Primary Tumors in Mice(B6C3F1) - INDIUM PHOSPHIDE
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.03 0.1MG/M3 0.3MG/M3 |CONTROL 0.03 0.1MG/M3 0.3MG/M3 |
| | MG/M3 STOP STOP | MG/M3 STOP STOP |
|=================================================================================================================================|
| |
|Intestine Small: Ileum |
| Carcinoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # |# # # # |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 0/50 (0%) 2/50 (4%) 1/50 (2%) |0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) |
|POLY-3 ADJUSTED (b)| 0.0% 0.0% 4.7% 2.4% |0.0% 0.0% 0.0% 0.0% |
|TERMINAL (d) | 0/37 (0%) 0/24 (0%) 0/29 (0%) 1/27 (4%) |0/42 (0%) 0/13 (0%) 0/33 (0%) 0/21 (0%) |
|FIRST INCIDENCE | --- --- 669 733 (T) |--- --- --- --- |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.311 (e) P=0.191 P=0.437 |(e) (e) (e) (e) |
|POLY 3 | P=0.329 (e) P=0.220 P=0.478 |(e) (e) (e) (e) |
|POLY 1.5 | P=0.339 (e) P=0.227 P=0.487 |(e) (e) (e) (e) |
|POLY 6 | P=0.313 (e) P=0.211 P=0.467 |(e) (e) (e) (e) |
|LOGISTIC REGRESSION| P=0.345 (e) P=0.262 P=0.437 |(e) (e) (e) (e) |
|COCH-ARM / FISHERS | P=0.350 (e) P=0.247 P=0.500 |(e) (e) (e) (e) |
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.03 0.1MG/M3 0.3MG/M3 |CONTROL 0.03 0.1MG/M3 0.3MG/M3 |
| | MG/M3 STOP STOP | MG/M3 STOP STOP |
|=================================================================================================================================|
| |
|Intestine Small: Jejunum |
| Carcinoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # |# # # # |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 1/50 (2%) 3/50 (6%) 2/50 (4%) |1/50 (2%) 0/50 (0%) 0/50 (0%) 0/50 (0%) |
|POLY-3 ADJUSTED (b)| 0.0% 2.6% 7.1% 4.8% |2.1% 0.0% 0.0% 0.0% |
|TERMINAL (d) | 0/37 (0%) 1/24 (4%) 2/29 (7%) 1/27 (4%) |1/42 (2%) 0/13 (0%) 0/33 (0%) 0/21 (0%) |
|FIRST INCIDENCE | --- 733 (T) 728 608 |735 (T) --- --- --- |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.213 P=0.414 P=0.085 P=0.194 |P=0.530N P=0.733N P=0.548N P=0.638N |
|POLY 3 | P=0.231 P=0.468 P=0.103 P=0.216 |P=0.438N P=0.547N P=0.504N P=0.541N |
|POLY 1.5 | P=0.242 P=0.480 P=0.110 P=0.224 |P=0.455N P=0.525N P=0.501N P=0.524N |
|POLY 6 | P=0.216 P=0.455 P=0.096 P=0.206 |P=0.414N P=0.579N P=0.511N P=0.563N |
|LOGISTIC REGRESSION| P=0.236 P=0.414 P=0.081 P=0.264 |P=0.530N (e) (e) (e) |
|COCH-ARM / FISHERS | P=0.256 P=0.500 P=0.121 P=0.247 |P=0.474N P=0.500N P=0.500N P=0.500N |
|=================================================================================================================================|
Date: 02/24/00 EXPERIMENT: 88124 TEST: 04 Page 4
Statistical Analysis of Primary Tumors in Mice(B6C3F1) - INDIUM PHOSPHIDE
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.03 0.1MG/M3 0.3MG/M3 |CONTROL 0.03 0.1MG/M3 0.3MG/M3 |
| | MG/M3 STOP STOP | MG/M3 STOP STOP |
|=================================================================================================================================|
| |
|Intestine Small: Site Unspecified |
| Carcinoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # |# # # # |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 1/50 (2%) 5/50 (10%) 3/50 (6%) |1/50 (2%) 0/50 (0%) 0/50 (0%) 0/50 (0%) |
|POLY-3 ADJUSTED (b)| 0.0% 2.6% 11.7% 7.2% |2.1% 0.0% 0.0% 0.0% |
|TERMINAL (d) | 0/37 (0%) 1/24 (4%) 2/29 (7%) 2/27 (7%) |1/42 (2%) 0/13 (0%) 0/33 (0%) 0/21 (0%) |
|FIRST INCIDENCE | --- 733 (T) 669 608 |735 (T) --- --- --- |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.109 P=0.414 P=0.019 * P=0.083 |P=0.530N P=0.733N P=0.548N P=0.638N |
|POLY 3 | P=0.123 P=0.468 P=0.024 * P=0.102 |P=0.438N P=0.547N P=0.504N P=0.541N |
|POLY 1.5 | P=0.132 P=0.480 P=0.027 * P=0.109 |P=0.455N P=0.525N P=0.501N P=0.524N |
|POLY 6 | P=0.111 P=0.455 P=0.021 * P=0.094 |P=0.414N P=0.579N P=0.511N P=0.563N |
|LOGISTIC REGRESSION| P=0.132 P=0.414 P=0.026 * P=0.118 |P=0.530N (e) (e) (e) |
|COCH-ARM / FISHERS | P=0.145 P=0.500 P=0.028 * P=0.121 |P=0.474N P=0.500N P=0.500N P=0.500N |
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.03 0.1MG/M3 0.3MG/M3 |CONTROL 0.03 0.1MG/M3 0.3MG/M3 |
| | MG/M3 STOP STOP | MG/M3 STOP STOP |
|=================================================================================================================================|
| |
|Intestine Small: Site Unspecified |
| Carcinoma or Adenoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # |# # # # |
|----------- | | |
|OVERALL (a) | 1/50 (2%) 2/50 (4%) 6/50 (12%) 3/50 (6%) |1/50 (2%) 0/50 (0%) 0/50 (0%) 0/50 (0%) |
|POLY-3 ADJUSTED (b)| 2.2% 5.0% 14.1% 7.2% |2.1% 0.0% 0.0% 0.0% |
|TERMINAL (d) | 1/37 (3%) 1/24 (4%) 3/29 (10%) 2/27 (7%) |1/42 (2%) 0/13 (0%) 0/33 (0%) 0/21 (0%) |
|FIRST INCIDENCE | 733 (T) 571 669 608 |735 (T) --- --- --- |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.267 P=0.377 P=0.032 * P=0.218 |P=0.530N P=0.733N P=0.548N P=0.638N |
|POLY 3 | P=0.295 P=0.448 P=0.044 * P=0.271 |P=0.438N P=0.547N P=0.504N P=0.541N |
|POLY 1.5 | P=0.312 P=0.467 P=0.049 * P=0.285 |P=0.455N P=0.525N P=0.501N P=0.524N |
|POLY 6 | P=0.271 P=0.430 P=0.038 * P=0.255 |P=0.414N P=0.579N P=0.511N P=0.563N |
|LOGISTIC REGRESSION| P=0.318 P=0.515 P=0.040 * P=0.284 |P=0.530N (e) (e) (e) |
|COCH-ARM / FISHERS | P=0.333 P=0.500 P=0.056 P=0.309 |P=0.474N P=0.500N P=0.500N P=0.500N |
|=================================================================================================================================|
Date: 02/24/00 EXPERIMENT: 88124 TEST: 04 Page 5
Statistical Analysis of Primary Tumors in Mice(B6C3F1) - INDIUM PHOSPHIDE
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.03 0.1MG/M3 0.3MG/M3 |CONTROL 0.03 0.1MG/M3 0.3MG/M3 |
| | MG/M3 STOP STOP | MG/M3 STOP STOP |
|=================================================================================================================================|
| |
|Islets, Pancreatic |
| Adenoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 3/50 (6%) 0/50 (0%) 0/49 (0%) 0/47 (0%) |0/50 (0%) 0/49 (0%) 2/50 (4%) 0/50 (0%) |
|POLY-3 ADJUSTED (b)| 6.4% 0.0% 0.0% 0.0% |0.0% 0.0% 4.3% 0.0% |
|TERMINAL (d) | 1/37 (3%) 0/24 (0%) 0/29 (0%) 0/27 (0%) |0/42 (0%) 0/13 (0%) 0/33 (0%) 0/21 (0%) |
|FIRST INCIDENCE | 561 --- --- --- |--- --- 699 --- |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.146N P=0.177N P=0.147N P=0.156N |P=0.715 (e) P=0.199 (e) |
|POLY 3 | P=0.116N P=0.155N P=0.142N P=0.148N |P=0.701 (e) P=0.233 (e) |
|POLY 1.5 | P=0.123N P=0.141N P=0.134N P=0.140N |P=0.721N (e) P=0.237 (e) |
|POLY 6 | P=0.111N P=0.172N P=0.154N P=0.160N |P=0.664 (e) P=0.226 (e) |
|LOGISTIC REGRESSION| P=0.144N P=0.051N P=0.048N* P=0.055N |P=0.735N (e) P=0.237 (e) |
|COCH-ARM / FISHERS | P=0.141N P=0.121N P=0.125N P=0.133N |P=0.695N (e) P=0.247 (e) |
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.03 0.1MG/M3 0.3MG/M3 |CONTROL 0.03 0.1MG/M3 0.3MG/M3 |
| | MG/M3 STOP STOP | MG/M3 STOP STOP |
|=================================================================================================================================|
| |
|Liver |
| Hemangiosarcoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 2/50 (4%) 1/50 (2%) 0/50 (0%) 2/50 (4%) |0/50 (0%) 1/50 (2%) 0/50 (0%) 1/50 (2%) |
|POLY-3 ADJUSTED (b)| 4.3% 2.5% 0.0% 4.8% |0.0% 2.7% 0.0% 2.6% |
|TERMINAL (d) | 1/37 (3%) 0/24 (0%) 0/29 (0%) 2/27 (7%) |0/42 (0%) 0/13 (0%) 0/33 (0%) 0/21 (0%) |
|FIRST INCIDENCE | 669 530 --- 733 (T) |--- 674 --- 727 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.466 P=0.588N P=0.287N P=0.584 |P=0.400 P=0.398 (e) P=0.380 |
|POLY 3 | P=0.505 P=0.553N P=0.259N P=0.652 |P=0.410 P=0.454 (e) P=0.459 |
|POLY 1.5 | P=0.510 P=0.534N P=0.250N P=0.670 |P=0.432 P=0.476 (e) P=0.476 |
|POLY 6 | P=0.496 P=0.573N P=0.272N P=0.630 |P=0.379 P=0.423 (e) P=0.437 |
|LOGISTIC REGRESSION| P=0.514 P=0.393N P=0.238N P=0.642 |P=0.443 P=0.515 (e) P=0.416 |
|COCH-ARM / FISHERS | P=0.512 P=0.500N P=0.247N P=0.691N |P=0.464 P=0.500 (e) P=0.500 |
|=================================================================================================================================|
Date: 02/24/00 EXPERIMENT: 88124 TEST: 04 Page 6
Statistical Analysis of Primary Tumors in Mice(B6C3F1) - INDIUM PHOSPHIDE
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.03 0.1MG/M3 0.3MG/M3 |CONTROL 0.03 0.1MG/M3 0.3MG/M3 |
| | MG/M3 STOP STOP | MG/M3 STOP STOP |
|=================================================================================================================================|
| |
|Liver |
| Hepatocellular Adenoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 17/50 (34%) 24/50 (48%) 23/50 (46%) 32/50 (64%) |12/50 (24%) 14/50 (28%) 18/50 (36%) 14/50 (28%) |
|POLY-3 ADJUSTED (b)| 36.5% 58.9% 51.8% 70.5% |25.6% 36.2% 37.7% 34.7% |
|TERMINAL (d) | 15/37 (41%) 15/24 (63%) 18/29 (62%) 21/27 (78%) |12/42 (29%) 5/13 (39%) 10/33 (30%) 6/21 (29%) |
|FIRST INCIDENCE | 664 562 481 370 |735 (T) 589 617 496 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P<0.001 ** P=0.003 ** P=0.025 * P<0.001 ** |P=0.135 P<0.001 ** P=0.053 P=0.028 * |
|POLY 3 | P=0.002 ** P=0.026 * P=0.099 P<0.001 ** |P=0.315 P=0.205 P=0.148 P=0.245 |
|POLY 1.5 | P=0.002 ** P=0.047 * P=0.121 P<0.001 ** |P=0.368 P=0.294 P=0.147 P=0.308 |
|POLY 6 | P<0.001 ** P=0.015 * P=0.074 P<0.001 ** |P=0.253 P=0.107 P=0.146 P=0.178 |
|LOGISTIC REGRESSION| P<0.001 ** P=0.010 * P=0.076 P<0.001 ** |P=0.298 P=0.051 P=0.133 P=0.223 |
|COCH-ARM / FISHERS | P=0.004 ** P=0.111 P=0.154 P=0.002 ** |P=0.455 P=0.410 P=0.138 P=0.410 |
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.03 0.1MG/M3 0.3MG/M3 |CONTROL 0.03 0.1MG/M3 0.3MG/M3 |
| | MG/M3 STOP STOP | MG/M3 STOP STOP |
|=================================================================================================================================|
| |
|Liver |
| Hepatocellular Carcinoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 11/50 (22%) 22/50 (44%) 23/50 (46%) 16/50 (32%) |6/50 (12%) 17/50 (34%) 8/50 (16%) 10/50 (20%) |
|POLY-3 ADJUSTED (b)| 23.2% 46.4% 47.3% 36.1% |12.7% 41.7% 17.4% 24.7% |
|TERMINAL (d) | 5/37 (14%) 6/24 (25%) 6/29 (21%) 7/27 (26%) |4/42 (10%) 5/13 (39%) 7/33 (21%) 2/21 (10%) |
|FIRST INCIDENCE | 607 331 478 562 |626 489 691 594 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.392 P=0.005 ** P=0.007 ** P=0.070 |P=0.331 P<0.001 ** P=0.238 P=0.038 * |
|POLY 3 | P=0.410 P=0.014 * P=0.010 * P=0.130 |P=0.459 P<0.001 ** P=0.365 P=0.120 |
|POLY 1.5 | P=0.458 P=0.014 * P=0.009 ** P=0.149 |P=0.522 P=0.003 ** P=0.380 P=0.150 |
|POLY 6 | P=0.361 P=0.013 * P=0.012 * P=0.111 |P=0.384 P<0.001 ** P=0.336 P=0.091 |
|LOGISTIC REGRESSION| P=0.466N P=0.146 P=0.040 * P=0.208 |P=0.514N P=0.007 ** P=0.365 P=0.201 |
|COCH-ARM / FISHERS | P=0.540 P=0.016 * P=0.010 * P=0.184 |P=0.501N P=0.008 ** P=0.387 P=0.207 |
|=================================================================================================================================|
Date: 02/24/00 EXPERIMENT: 88124 TEST: 04 Page 7
Statistical Analysis of Primary Tumors in Mice(B6C3F1) - INDIUM PHOSPHIDE
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.03 0.1MG/M3 0.3MG/M3 |CONTROL 0.03 0.1MG/M3 0.3MG/M3 |
| | MG/M3 STOP STOP | MG/M3 STOP STOP |
|=================================================================================================================================|
| |
|Liver |
| Hepatocellular Carcinoma or Hepatoblastoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 11/50 (22%) 22/50 (44%) 23/50 (46%) 16/50 (32%) |6/50 (12%) 17/50 (34%) 8/50 (16%) 10/50 (20%) |
|POLY-3 ADJUSTED (b)| 23.2% 46.4% 47.3% 36.1% |12.7% 41.7% 17.4% 24.7% |
|TERMINAL (d) | 5/37 (14%) 6/24 (25%) 6/29 (21%) 7/27 (26%) |4/42 (10%) 5/13 (39%) 7/33 (21%) 2/21 (10%) |
|FIRST INCIDENCE | 607 331 478 562 |626 489 691 594 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.392 P=0.005 ** P=0.007 ** P=0.070 |P=0.331 P<0.001 ** P=0.238 P=0.038 * |
|POLY 3 | P=0.410 P=0.014 * P=0.010 * P=0.130 |P=0.459 P<0.001 ** P=0.365 P=0.120 |
|POLY 1.5 | P=0.458 P=0.014 * P=0.009 ** P=0.149 |P=0.522 P=0.003 ** P=0.380 P=0.150 |
|POLY 6 | P=0.361 P=0.013 * P=0.012 * P=0.111 |P=0.384 P<0.001 ** P=0.336 P=0.091 |
|LOGISTIC REGRESSION| P=0.466N P=0.146 P=0.040 * P=0.208 |P=0.514N P=0.007 ** P=0.365 P=0.201 |
|COCH-ARM / FISHERS | P=0.540 P=0.016 * P=0.010 * P=0.184 |P=0.501N P=0.008 ** P=0.387 P=0.207 |
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.03 0.1MG/M3 0.3MG/M3 |CONTROL 0.03 0.1MG/M3 0.3MG/M3 |
| | MG/M3 STOP STOP | MG/M3 STOP STOP |
|=================================================================================================================================|
| |
|Liver |
| Hepatocellular Carcinoma or Hepatocellular Adenoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 26/50 (52%) 40/50 (80%) 37/50 (74%) 39/50 (78%) |18/50 (36%) 28/50 (56%) 24/50 (48%) 23/50 (46%) |
|POLY-3 ADJUSTED (b)| 54.6% 83.2% 76.1% 82.7% |38.1% 66.7% 50.1% 54.2% |
|TERMINAL (d) | 19/37 (51%) 19/24 (79%) 20/29 (69%) 22/27 (82%) |16/42 (38%) 10/13 (77%) 15/33 (46%) 8/21 (38%) |
|FIRST INCIDENCE | 607 331 478 370 |626 489 617 496 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.030 * P<0.001 ** P=0.005 ** P<0.001 ** |P=0.093 P<0.001 ** P=0.046 * P=0.003 ** |
|POLY 3 | P=0.023 * P<0.001 ** P=0.019 * P=0.002 ** |P=0.304 P=0.004 ** P=0.163 P=0.090 |
|POLY 1.5 | P=0.030 * P=0.002 ** P=0.018 * P=0.003 ** |P=0.363 P=0.012 * P=0.165 P=0.126 |
|POLY 6 | P=0.019 * P<0.001 ** P=0.021 * P<0.001 ** |P=0.250 P<0.001 ** P=0.156 P=0.061 |
|LOGISTIC REGRESSION| P=0.052 P=0.004 ** P=0.022 * P=0.002 ** |P=0.330 P=0.002 ** P=0.148 P=0.092 |
|COCH-ARM / FISHERS | P=0.050 P=0.003 ** P=0.019 * P=0.006 ** |P=0.479 P=0.035 * P=0.156 P=0.208 |
|=================================================================================================================================|
Date: 02/24/00 EXPERIMENT: 88124 TEST: 04 Page 8
Statistical Analysis of Primary Tumors in Mice(B6C3F1) - INDIUM PHOSPHIDE
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.03 0.1MG/M3 0.3MG/M3 |CONTROL 0.03 0.1MG/M3 0.3MG/M3 |
| | MG/M3 STOP STOP | MG/M3 STOP STOP |
|=================================================================================================================================|
| |
|Liver |
| Hepatocellular Carcinoma, Hepatocellular Adenoma, |
| or Hepatoblastoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 26/50 (52%) 40/50 (80%) 37/50 (74%) 39/50 (78%) |18/50 (36%) 28/50 (56%) 24/50 (48%) 23/50 (46%) |
|POLY-3 ADJUSTED (b)| 54.6% 83.2% 76.1% 82.7% |38.1% 66.7% 50.1% 54.2% |
|TERMINAL (d) | 19/37 (51%) 19/24 (79%) 20/29 (69%) 22/27 (82%) |16/42 (38%) 10/13 (77%) 15/33 (46%) 8/21 (38%) |
|FIRST INCIDENCE | 607 331 478 370 |626 489 617 496 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.030 * P<0.001 ** P=0.005 ** P<0.001 ** |P=0.093 P<0.001 ** P=0.046 * P=0.003 ** |
|POLY 3 | P=0.023 * P<0.001 ** P=0.019 * P=0.002 ** |P=0.304 P=0.004 ** P=0.163 P=0.090 |
|POLY 1.5 | P=0.030 * P=0.002 ** P=0.018 * P=0.003 ** |P=0.363 P=0.012 * P=0.165 P=0.126 |
|POLY 6 | P=0.019 * P<0.001 ** P=0.021 * P<0.001 ** |P=0.250 P<0.001 ** P=0.156 P=0.061 |
|LOGISTIC REGRESSION| P=0.052 P=0.004 ** P=0.022 * P=0.002 ** |P=0.330 P=0.002 ** P=0.148 P=0.092 |
|COCH-ARM / FISHERS | P=0.050 P=0.003 ** P=0.019 * P=0.006 ** |P=0.479 P=0.035 * P=0.156 P=0.208 |
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.03 0.1MG/M3 0.3MG/M3 |CONTROL 0.03 0.1MG/M3 0.3MG/M3 |
| | MG/M3 STOP STOP | MG/M3 STOP STOP |
|=================================================================================================================================|
| |
|Lung |
| Alveolar/Bronchiolar Adenoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 13/50 (26%) 9/50 (18%) 7/50 (14%) 13/50 (26%) |3/50 (6%) 6/50 (12%) 10/50 (20%) 7/50 (14%) |
|POLY-3 ADJUSTED (b)| 28.2% 22.4% 16.3% 30.7% |6.4% 16.1% 21.5% 18.0% |
|TERMINAL (d) | 12/37 (32%) 5/24 (21%) 4/29 (14%) 10/27 (37%) |2/42 (5%) 4/13 (31%) 6/33 (18%) 4/21 (19%) |
|FIRST INCIDENCE | 726 571 657 562 |699 645 658 608 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.214 P=0.566 P=0.252N P=0.256 |P=0.085 P=0.008 ** P=0.019 * P=0.026 * |
|POLY 3 | P=0.327 P=0.356N P=0.138N P=0.490 |P=0.146 P=0.142 P=0.033 * P=0.092 |
|POLY 1.5 | P=0.341 P=0.311N P=0.124N P=0.530 |P=0.182 P=0.186 P=0.035 * P=0.116 |
|POLY 6 | P=0.303 P=0.397N P=0.155N P=0.442 |P=0.106 P=0.092 P=0.029 * P=0.068 |
|LOGISTIC REGRESSION| P=0.279 P=0.441N P=0.192N P=0.373 |P=0.144 P=0.048 * P=0.035 * P=0.096 |
|COCH-ARM / FISHERS | P=0.352 P=0.235N P=0.105N P=0.590N |P=0.244 P=0.243 P=0.036 * P=0.159 |
|=================================================================================================================================|
Date: 02/24/00 EXPERIMENT: 88124 TEST: 04 Page 9
Statistical Analysis of Primary Tumors in Mice(B6C3F1) - INDIUM PHOSPHIDE
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.03 0.1MG/M3 0.3MG/M3 |CONTROL 0.03 0.1MG/M3 0.3MG/M3 |
| | MG/M3 STOP STOP | MG/M3 STOP STOP |
|=================================================================================================================================|
| |
|Lung |
| Alveolar/Bronchiolar Carcinoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 6/50 (12%) 15/50 (30%) 22/50 (44%) 13/50 (26%) |1/50 (2%) 6/50 (12%) 5/50 (10%) 7/50 (14%) |
|POLY-3 ADJUSTED (b)| 12.9% 36.5% 48.6% 29.7% |2.1% 15.8% 10.8% 17.6% |
|TERMINAL (d) | 4/37 (11%) 9/24 (38%) 14/29 (48%) 6/27 (22%) |1/42 (2%) 2/13 (15%) 3/33 (9%) 1/21 (5%) |
|FIRST INCIDENCE | 664 457 478 589 |735 (T) 580 664 600 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.168 P=0.003 ** P<0.001 ** P=0.022 * |P=0.035 * P=0.003 ** P=0.073 P=0.007 ** |
|POLY 3 | P=0.224 P=0.008 ** P<0.001 ** P=0.042 * |P=0.053 P=0.029 * P=0.099 P=0.016 * |
|POLY 1.5 | P=0.245 P=0.012 * P<0.001 ** P=0.049 * |P=0.067 P=0.040 * P=0.102 P=0.021 * |
|POLY 6 | P=0.202 P=0.006 ** P<0.001 ** P=0.036 * |P=0.038 * P=0.017 * P=0.093 P=0.012 * |
|LOGISTIC REGRESSION| P=0.269 P=0.012 * P<0.001 ** P=0.066 |P=0.083 P=0.030 * P=0.103 P=0.032 * |
|COCH-ARM / FISHERS | P=0.281 P=0.024 * P<0.001 ** P=0.062 |P=0.094 P=0.056 P=0.102 P=0.030 * |
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.03 0.1MG/M3 0.3MG/M3 |CONTROL 0.03 0.1MG/M3 0.3MG/M3 |
| | MG/M3 STOP STOP | MG/M3 STOP STOP |
|=================================================================================================================================|
| |
|Lung |
| Alveolar/Bronchiolar Carcinoma or Alveolar/Bronchiolar |
| Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 18/50 (36%) 23/50 (46%) 24/50 (48%) 21/50 (42%) |4/50 (8%) 11/50 (22%) 15/50 (30%) 14/50 (28%) |
|POLY-3 ADJUSTED (b)| 38.6% 54.5% 52.6% 47.1% |8.5% 28.8% 31.9% 34.4% |
|TERMINAL (d) | 15/37 (41%) 13/24 (54%) 15/29 (52%) 12/27 (44%) |3/42 (7%) 6/13 (46%) 9/33 (27%) 5/21 (24%) |
|FIRST INCIDENCE | 664 457 478 562 |699 580 658 600 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.262 P=0.015 * P=0.036 * P=0.082 |P=0.005 ** P<0.001 ** P=0.002 ** P<0.001 ** |
|POLY 3 | P=0.451 P=0.094 P=0.122 P=0.270 |P=0.014 * P=0.014 * P=0.004 ** P=0.002 ** |
|POLY 1.5 | P=0.462 P=0.126 P=0.135 P=0.294 |P=0.021 * P=0.025 * P=0.004 ** P=0.004 ** |
|POLY 6 | P=0.439 P=0.075 P=0.109 P=0.252 |P=0.008 ** P=0.005 ** P=0.003 ** P<0.001 ** |
|LOGISTIC REGRESSION| P=0.432 P=0.066 P=0.110 P=0.232 |P=0.018 * P=0.006 ** P=0.005 ** P=0.005 ** |
|COCH-ARM / FISHERS | P=0.478 P=0.208 P=0.156 P=0.341 |P=0.040 * P=0.045 * P=0.005 ** P=0.009 ** |
|=================================================================================================================================|
Date: 02/24/00 EXPERIMENT: 88124 TEST: 04 Page 10
Statistical Analysis of Primary Tumors in Mice(B6C3F1) - INDIUM PHOSPHIDE
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.03 0.1MG/M3 0.3MG/M3 |CONTROL 0.03 0.1MG/M3 0.3MG/M3 |
| | MG/M3 STOP STOP | MG/M3 STOP STOP |
|=================================================================================================================================|
| |
|Ovary |
| Granulosa Cell Tumor Benign |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | |0/47 (0%) 0/46 (0%) 2/44 (5%) 0/47 (0%) |
|POLY-3 ADJUSTED (b)| |0.0% 0.0% 5.0% 0.0% |
|TERMINAL (d) | |0/39 (0%) 0/13 (0%) 2/29 (7%) 0/20 (0%) |
|FIRST INCIDENCE | |--- --- 735 (T) --- |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | |P=0.704 (e) P=0.176 (e) |
|POLY 3 | |P=0.706 (e) P=0.217 (e) |
|POLY 1.5 | |P=0.718N (e) P=0.221 (e) |
|POLY 6 | |P=0.672 (e) P=0.209 (e) |
|LOGISTIC REGRESSION| |(e) (e) P=0.176 (e) |
|COCH-ARM / FISHERS | |P=0.693N (e) P=0.231 (e) |
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.03 0.1MG/M3 0.3MG/M3 |CONTROL 0.03 0.1MG/M3 0.3MG/M3 |
| | MG/M3 STOP STOP | MG/M3 STOP STOP |
|=================================================================================================================================|
| |
|Pituitary Gland: Pars Distalis or Unspecified Site |
| Adenoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 0/48 (0%) 0/47 (0%) 0/45 (0%) 0/50 (0%) |10/50 (20%) 7/50 (14%) 11/48 (23%) 7/49 (14%) |
|POLY-3 ADJUSTED (b)| 0.0% 0.0% 0.0% 0.0% |21.2% 18.1% 24.8% 18.5% |
|TERMINAL (d) | 0/36 (0%) 0/23 (0%) 0/27 (0%) 0/27 (0%) |9/42 (21%) 3/13 (23%) 9/32 (28%) 4/21 (19%) |
|FIRST INCIDENCE | --- --- --- --- |664 514 687 619 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | (e) (e) (e) (e) |P=0.472 P=0.192 P=0.264 P=0.364 |
|POLY 3 | (e) (e) (e) (e) |P=0.488N P=0.462N P=0.439 P=0.486N |
|POLY 1.5 | (e) (e) (e) (e) |P=0.439N P=0.381N P=0.454 P=0.412N |
|POLY 6 | (e) (e) (e) (e) |P=0.551N P=0.592N P=0.408 P=0.580N |
|LOGISTIC REGRESSION| (e) (e) (e) (e) |P=0.496N P=0.395N P=0.395 P=0.608N |
|COCH-ARM / FISHERS | (e) (e) (e) (e) |P=0.362N P=0.298N P=0.458 P=0.314N |
|=================================================================================================================================|
Date: 02/24/00 EXPERIMENT: 88124 TEST: 04 Page 11
Statistical Analysis of Primary Tumors in Mice(B6C3F1) - INDIUM PHOSPHIDE
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.03 0.1MG/M3 0.3MG/M3 |CONTROL 0.03 0.1MG/M3 0.3MG/M3 |
| | MG/M3 STOP STOP | MG/M3 STOP STOP |
|=================================================================================================================================|
| |
|Pituitary Gland: Pars Distalis or Unspecified Site |
| Carcinoma or Adenoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 0/48 (0%) 0/47 (0%) 0/45 (0%) 0/50 (0%) |10/50 (20%) 7/50 (14%) 12/48 (25%) 8/49 (16%) |
|POLY-3 ADJUSTED (b)| 0.0% 0.0% 0.0% 0.0% |21.2% 18.1% 27.0% 21.1% |
|TERMINAL (d) | 0/36 (0%) 0/23 (0%) 0/27 (0%) 0/27 (0%) |9/42 (21%) 3/13 (23%) 9/32 (28%) 4/21 (19%) |
|FIRST INCIDENCE | --- --- --- --- |664 514 687 619 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | (e) (e) (e) (e) |P=0.343 P=0.192 P=0.191 P=0.255 |
|POLY 3 | (e) (e) (e) (e) |P=0.510 P=0.462N P=0.344 P=0.598N |
|POLY 1.5 | (e) (e) (e) (e) |P=0.560N P=0.381N P=0.359 P=0.523N |
|POLY 6 | (e) (e) (e) (e) |P=0.445 P=0.592N P=0.314 P=0.519 |
|LOGISTIC REGRESSION| (e) (e) (e) (e) |P=0.505 P=0.395N P=0.300 P=0.510 |
|COCH-ARM / FISHERS | (e) (e) (e) (e) |P=0.479N P=0.298N P=0.363 P=0.416N |
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.03 0.1MG/M3 0.3MG/M3 |CONTROL 0.03 0.1MG/M3 0.3MG/M3 |
| | MG/M3 STOP STOP | MG/M3 STOP STOP |
|=================================================================================================================================|
| |
|Pituitary Gland: Pars Intermedia |
| Adenoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 0/48 (0%) 0/47 (0%) 2/45 (4%) 1/50 (2%) |0/50 (0%) 1/50 (2%) 0/48 (0%) 1/49 (2%) |
|POLY-3 ADJUSTED (b)| 0.0% 0.0% 5.2% 2.4% |0.0% 2.7% 0.0% 2.7% |
|TERMINAL (d) | 0/36 (0%) 0/23 (0%) 1/27 (4%) 1/27 (4%) |0/42 (0%) 1/13 (8%) 0/32 (0%) 1/21 (5%) |
|FIRST INCIDENCE | --- --- 644 733 (T) |--- 735 (T) --- 735 (T) |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.323 (e) P=0.199 P=0.443 |P=0.382 P=0.267 (e) P=0.362 |
|POLY 3 | P=0.341 (e) P=0.205 P=0.485 |P=0.405 P=0.453 (e) P=0.455 |
|POLY 1.5 | P=0.353 (e) P=0.212 P=0.495 |P=0.428 P=0.475 (e) P=0.472 |
|POLY 6 | P=0.324 (e) P=0.197 P=0.474 |P=0.375 P=0.420 (e) P=0.434 |
|LOGISTIC REGRESSION| P=0.355 (e) P=0.232 P=0.443 |(e) P=0.267 (e) P=0.362 |
|COCH-ARM / FISHERS | P=0.366 (e) P=0.231 P=0.510 |P=0.459 P=0.500 (e) P=0.495 |
|=================================================================================================================================|
Date: 02/24/00 EXPERIMENT: 88124 TEST: 04 Page 12
Statistical Analysis of Primary Tumors in Mice(B6C3F1) - INDIUM PHOSPHIDE
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.03 0.1MG/M3 0.3MG/M3 |CONTROL 0.03 0.1MG/M3 0.3MG/M3 |
| | MG/M3 STOP STOP | MG/M3 STOP STOP |
|=================================================================================================================================|
| |
|Skin |
| Hemangiosarcoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # |# # # # |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 0/50 (0%) 0/50 (0%) 1/50 (2%) |2/50 (4%) 2/50 (4%) 0/50 (0%) 0/50 (0%) |
|POLY-3 ADJUSTED (b)| 0.0% 0.0% 0.0% 2.4% |4.2% 5.4% 0.0% 0.0% |
|TERMINAL (d) | 0/37 (0%) 0/24 (0%) 0/29 (0%) 0/27 (0%) |1/42 (2%) 0/13 (0%) 0/33 (0%) 0/21 (0%) |
|FIRST INCIDENCE | --- --- --- 687 |664 686 --- --- |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.198 (e) (e) P=0.461 |P=0.159N P=0.397 P=0.269N P=0.368N |
|POLY 3 | P=0.209 (e) (e) P=0.479 |P=0.135N P=0.606 P=0.243N P=0.288N |
|POLY 1.5 | P=0.212 (e) (e) P=0.488 |P=0.129N P=0.648 P=0.239N P=0.266N |
|POLY 6 | P=0.204 (e) (e) P=0.469 |P=0.143N P=0.539 P=0.252N P=0.319N |
|LOGISTIC REGRESSION| P=0.213 (e) (e) P=0.511 |P=0.128N P=0.657 P=0.239N P=0.252N |
|COCH-ARM / FISHERS | P=0.214 (e) (e) P=0.500 |P=0.122N P=0.691N P=0.247N P=0.247N |
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.03 0.1MG/M3 0.3MG/M3 |CONTROL 0.03 0.1MG/M3 0.3MG/M3 |
| | MG/M3 STOP STOP | MG/M3 STOP STOP |
|=================================================================================================================================|
| |
|Spleen |
| Hemangiosarcoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 2/50 (4%) 0/50 (0%) 1/48 (2%) 0/48 (0%) |1/50 (2%) 2/49 (4%) 1/50 (2%) 0/49 (0%) |
|POLY-3 ADJUSTED (b)| 4.3% 0.0% 2.4% 0.0% |2.1% 5.4% 2.2% 0.0% |
|TERMINAL (d) | 1/37 (3%) 0/24 (0%) 0/29 (0%) 0/27 (0%) |0/42 (0%) 1/13 (8%) 1/33 (3%) 0/21 (0%) |
|FIRST INCIDENCE | 669 --- 681 --- |664 706 735 (T) --- |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.307N P=0.312N P=0.573N P=0.302N |P=0.300N P=0.222 P=0.731 P=0.585N |
|POLY 3 | P=0.263N P=0.277N P=0.541N P=0.268N |P=0.278N P=0.415 P=0.754 P=0.544N |
|POLY 1.5 | P=0.268N P=0.262N P=0.530N P=0.259N |P=0.259N P=0.452 P=0.759 P=0.527N |
|POLY 6 | P=0.261N P=0.293N P=0.554N P=0.281N |P=0.306N P=0.360 P=0.746 P=0.566N |
|LOGISTIC REGRESSION| P=0.282N P=0.256N P=0.504N P=0.247N |P=0.258N P=0.430 P=0.761 P=0.482N |
|COCH-ARM / FISHERS | P=0.280N P=0.247N P=0.515N P=0.258N |P=0.234N P=0.492 P=0.753N P=0.505N |
|=================================================================================================================================|
Date: 02/24/00 EXPERIMENT: 88124 TEST: 04 Page 13
Statistical Analysis of Primary Tumors in Mice(B6C3F1) - INDIUM PHOSPHIDE
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.03 0.1MG/M3 0.3MG/M3 |CONTROL 0.03 0.1MG/M3 0.3MG/M3 |
| | MG/M3 STOP STOP | MG/M3 STOP STOP |
|=================================================================================================================================|
| |
|Stomach, Forestomach |
| Squamous Cell Carcinoma or Papilloma Squamous |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # |# # # # |
|----------- | | |
|OVERALL (a) | 2/50 (4%) 0/50 (0%) 2/50 (4%) 0/50 (0%) |1/50 (2%) 0/50 (0%) 1/50 (2%) 0/50 (0%) |
|POLY-3 ADJUSTED (b)| 4.3% 0.0% 4.7% 0.0% |2.1% 0.0% 2.2% 0.0% |
|TERMINAL (d) | 2/37 (5%) 0/24 (0%) 2/29 (7%) 0/27 (0%) |0/42 (0%) 0/13 (0%) 1/33 (3%) 0/21 (0%) |
|FIRST INCIDENCE | 733 (T) --- 733 (T) --- |678 --- 735 (T) --- |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.330N P=0.338N P=0.605 P=0.310N |P=0.529N P=0.617N P=0.726 P=0.588N |
|POLY 3 | P=0.281N P=0.275N P=0.661 P=0.262N |P=0.466N P=0.548N P=0.755 P=0.542N |
|POLY 1.5 | P=0.281N P=0.261N P=0.675 P=0.252N |P=0.466N P=0.525N P=0.759 P=0.525N |
|POLY 6 | P=0.285N P=0.291N P=0.643 P=0.275N |P=0.467N P=0.581N P=0.746 P=0.565N |
|LOGISTIC REGRESSION| P=0.330N (e) P=0.605 (e) |P=0.490N P=0.490N P=0.762 P=0.494N |
|COCH-ARM / FISHERS | P=0.287N P=0.247N P=0.691N P=0.247N |P=0.464N P=0.500N P=0.753N P=0.500N |
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.03 0.1MG/M3 0.3MG/M3 |CONTROL 0.03 0.1MG/M3 0.3MG/M3 |
| | MG/M3 STOP STOP | MG/M3 STOP STOP |
|=================================================================================================================================|
| |
|Stomach, Forestomach |
| Squamous Cell Papilloma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # |# # # # |
|----------- | | |
|OVERALL (a) | 1/50 (2%) 0/50 (0%) 2/50 (4%) 0/50 (0%) |0/50 (0%) 0/50 (0%) 1/50 (2%) 0/50 (0%) |
|POLY-3 ADJUSTED (b)| 2.2% 0.0% 4.7% 0.0% |0.0% 0.0% 2.2% 0.0% |
|TERMINAL (d) | 1/37 (3%) 0/24 (0%) 2/29 (7%) 0/27 (0%) |0/42 (0%) 0/13 (0%) 1/33 (3%) 0/21 (0%) |
|FIRST INCIDENCE | 733 (T) --- 733 (T) --- |--- --- 735 (T) --- |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.499N P=0.586N P=0.415 P=0.563N |P=0.798 (e) P=0.452 (e) |
|POLY 3 | P=0.458N P=0.532N P=0.469 P=0.522N |P=0.782 (e) P=0.496 (e) |
|POLY 1.5 | P=0.455N P=0.520N P=0.482 P=0.513N |P=0.796N (e) P=0.499 (e) |
|POLY 6 | P=0.467N P=0.544N P=0.452 P=0.533N |P=0.756 (e) P=0.489 (e) |
|LOGISTIC REGRESSION| P=0.499N (e) P=0.415 (e) |(e) (e) P=0.452 (e) |
|COCH-ARM / FISHERS | P=0.455N P=0.500N P=0.500 P=0.500N |P=0.786N (e) P=0.500 (e) |
|=================================================================================================================================|
Date: 02/24/00 EXPERIMENT: 88124 TEST: 04 Page 14
Statistical Analysis of Primary Tumors in Mice(B6C3F1) - INDIUM PHOSPHIDE
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.03 0.1MG/M3 0.3MG/M3 |CONTROL 0.03 0.1MG/M3 0.3MG/M3 |
| | MG/M3 STOP STOP | MG/M3 STOP STOP |
|=================================================================================================================================|
| |
|Testes |
| Adenoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 2/50 (4%) 1/50 (2%) 1/50 (2%) 0/50 (0%) | |
|POLY-3 ADJUSTED (b)| 4.3% 2.5% 2.4% 0.0% | |
|TERMINAL (d) | 2/37 (5%) 0/24 (0%) 1/29 (3%) 0/27 (0%) | |
|FIRST INCIDENCE | 733 (T) 700 733 (T) --- | |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.228N P=0.625N P=0.585N P=0.310N | |
|POLY 3 | P=0.196N P=0.555N P=0.531N P=0.262N | |
|POLY 1.5 | P=0.195N P=0.535N P=0.518N P=0.252N | |
|POLY 6 | P=0.201N P=0.575N P=0.548N P=0.275N | |
|LOGISTIC REGRESSION| P=0.217N P=0.585N P=0.585N (e) | |
|COCH-ARM / FISHERS | P=0.194N P=0.500N P=0.500N P=0.247N | |
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.03 0.1MG/M3 0.3MG/M3 |CONTROL 0.03 0.1MG/M3 0.3MG/M3 |
| | MG/M3 STOP STOP | MG/M3 STOP STOP |
|=================================================================================================================================|
| |
|Uterus |
| Polyp Stromal |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # |# # # # |
|----------- | | |
|OVERALL (a) | |0/50 (0%) 1/50 (2%) 2/50 (4%) 2/50 (4%) |
|POLY-3 ADJUSTED (b)| |0.0% 2.7% 4.4% 5.3% |
|TERMINAL (d) | |0/42 (0%) 1/13 (8%) 2/33 (6%) 2/21 (10%) |
|FIRST INCIDENCE | |--- 735 (T) 735 (T) 735 (T) |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | |P=0.130 P=0.267 P=0.187 P=0.104 |
|POLY 3 | |P=0.175 P=0.453 P=0.232 P=0.194 |
|POLY 1.5 | |P=0.196 P=0.475 P=0.236 P=0.211 |
|POLY 6 | |P=0.148 P=0.420 P=0.225 P=0.174 |
|LOGISTIC REGRESSION| |(e) P=0.267 P=0.187 P=0.104 |
|COCH-ARM / FISHERS | |P=0.228 P=0.500 P=0.247 P=0.247 |
|=================================================================================================================================|
Date: 02/24/00 EXPERIMENT: 88124 TEST: 04 Page 15
Statistical Analysis of Primary Tumors in Mice(B6C3F1) - INDIUM PHOSPHIDE
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.03 0.1MG/M3 0.3MG/M3 |CONTROL 0.03 0.1MG/M3 0.3MG/M3 |
| | MG/M3 STOP STOP | MG/M3 STOP STOP |
|=================================================================================================================================|
| |
|All Organs |
| Hemangioma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # |# # # # |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 0/50 (0%) 2/50 (4%) 0/50 (0%) |1/50 (2%) 0/50 (0%) 1/50 (2%) 0/50 (0%) |
|POLY-3 ADJUSTED (b)| 0.0% 0.0% 4.7% 0.0% |2.1% 0.0% 2.2% 0.0% |
|TERMINAL (d) | 0/37 (0%) 0/24 (0%) 2/29 (7%) 0/27 (0%) |1/42 (2%) 0/13 (0%) 0/33 (0%) 0/21 (0%) |
|FIRST INCIDENCE | --- --- 733 (T) --- |735 (T) --- 672 --- |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.730N (e) P=0.186 (e) |P=0.532N P=0.733N P=0.731 P=0.638N |
|POLY 3 | P=0.713N (e) P=0.218 (e) |P=0.466N P=0.547N P=0.757 P=0.541N |
|POLY 1.5 | P=0.706N (e) P=0.226 (e) |P=0.466N P=0.525N P=0.760 P=0.524N |
|POLY 6 | P=0.723 (e) P=0.207 (e) |P=0.466N P=0.579N P=0.750 P=0.563N |
|LOGISTIC REGRESSION| (e) (e) P=0.186 (e) |P=0.486N (e) P=0.762 (e) |
|COCH-ARM / FISHERS | P=0.697N (e) P=0.247 (e) |P=0.464N P=0.500N P=0.753N P=0.500N |
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.03 0.1MG/M3 0.3MG/M3 |CONTROL 0.03 0.1MG/M3 0.3MG/M3 |
| | MG/M3 STOP STOP | MG/M3 STOP STOP |
|=================================================================================================================================|
| |
|All Organs |
| Hemangiosarcoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # |# # # # |
|----------- | | |
|OVERALL (a) | 3/50 (6%) 2/50 (4%) 1/50 (2%) 3/50 (6%) |3/50 (6%) 4/50 (8%) 1/50 (2%) 1/50 (2%) |
|POLY-3 ADJUSTED (b)| 6.5% 5.0% 2.4% 7.2% |6.4% 10.7% 2.2% 2.6% |
|TERMINAL (d) | 2/37 (5%) 1/24 (4%) 0/29 (0%) 2/27 (7%) |2/42 (5%) 1/13 (8%) 1/33 (3%) 0/21 (0%) |
|FIRST INCIDENCE | 669 530 681 687 |664 674 735 (T) 727 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.442 P=0.644N P=0.388N P=0.527 |P=0.246N P=0.122 P=0.375N P=0.535N |
|POLY 3 | P=0.493 P=0.569N P=0.338N P=0.611 |P=0.196N P=0.378 P=0.315N P=0.386N |
|POLY 1.5 | P=0.502 P=0.544N P=0.325N P=0.632 |P=0.179N P=0.434 P=0.308N P=0.351N |
|POLY 6 | P=0.479 P=0.595N P=0.357N P=0.584 |P=0.222N P=0.298 P=0.329N P=0.432N |
|LOGISTIC REGRESSION| P=0.502 P=0.482N P=0.317N P=0.601 |P=0.190N P=0.364 P=0.307N P=0.394N |
|COCH-ARM / FISHERS | P=0.509 P=0.500N P=0.309N P=0.661N |P=0.155N P=0.500 P=0.309N P=0.309N |
|=================================================================================================================================|
Date: 02/24/00 EXPERIMENT: 88124 TEST: 04 Page 16
Statistical Analysis of Primary Tumors in Mice(B6C3F1) - INDIUM PHOSPHIDE
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.03 0.1MG/M3 0.3MG/M3 |CONTROL 0.03 0.1MG/M3 0.3MG/M3 |
| | MG/M3 STOP STOP | MG/M3 STOP STOP |
|=================================================================================================================================|
| |
|All Organs |
| Hemangiosarcoma or Hemangioma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # |# # # # |
|----------- | | |
|OVERALL (a) | 3/50 (6%) 2/50 (4%) 3/50 (6%) 3/50 (6%) |4/50 (8%) 4/50 (8%) 2/50 (4%) 1/50 (2%) |
|POLY-3 ADJUSTED (b)| 6.5% 5.0% 7.1% 7.2% |8.5% 10.7% 4.3% 2.6% |
|TERMINAL (d) | 2/37 (5%) 1/24 (4%) 2/29 (7%) 2/27 (7%) |3/42 (7%) 1/13 (8%) 1/33 (3%) 0/21 (0%) |
|FIRST INCIDENCE | 669 530 681 687 |664 674 672 727 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.447 P=0.644N P=0.553 P=0.527 |P=0.193N P=0.179 P=0.418N P=0.407N |
|POLY 3 | P=0.500 P=0.569N P=0.620 P=0.611 |P=0.143N P=0.513 P=0.348N P=0.251N |
|POLY 1.5 | P=0.512 P=0.544N P=0.637 P=0.632 |P=0.129N P=0.575 P=0.340N P=0.219N |
|POLY 6 | P=0.479 P=0.595N P=0.597 P=0.584 |P=0.165N P=0.420 P=0.363N P=0.296N |
|LOGISTIC REGRESSION| P=0.508 P=0.482N P=0.617 P=0.601 |P=0.138N P=0.478 P=0.337N P=0.270N |
|COCH-ARM / FISHERS | P=0.524 P=0.500N P=0.661N P=0.661N |P=0.110N P=0.643N P=0.339N P=0.181N |
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.03 0.1MG/M3 0.3MG/M3 |CONTROL 0.03 0.1MG/M3 0.3MG/M3 |
| | MG/M3 STOP STOP | MG/M3 STOP STOP |
|=================================================================================================================================|
| |
|All Organs |
| Histiocytic Sarcoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # |# # # # |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 2/50 (4%) 0/50 (0%) 1/50 (2%) |1/50 (2%) 3/50 (6%) 1/50 (2%) 3/50 (6%) |
|POLY-3 ADJUSTED (b)| 0.0% 5.1% 0.0% 2.4% |2.1% 7.9% 2.2% 7.7% |
|TERMINAL (d) | 0/37 (0%) 0/24 (0%) 0/29 (0%) 0/27 (0%) |1/42 (2%) 0/13 (0%) 0/33 (0%) 0/21 (0%) |
|FIRST INCIDENCE | --- 700 --- 471 |735 (T) 533 691 512 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.595 P=0.178 (e) P=0.496 |P=0.258 P=0.123 P=0.717 P=0.185 |
|POLY 3 | P=0.586 P=0.203 (e) P=0.482 |P=0.283 P=0.235 P=0.757 P=0.245 |
|POLY 1.5 | P=0.601 P=0.215 (e) P=0.489 |P=0.308 P=0.267 P=0.760 P=0.269 |
|POLY 6 | P=0.568 P=0.192 (e) P=0.472 |P=0.251 P=0.191 P=0.750 P=0.216 |
|LOGISTIC REGRESSION| P=0.635 P=0.193 (e) P=0.906 |P=0.434 P=0.367 P=0.762 P=0.379 |
|COCH-ARM / FISHERS | P=0.622 P=0.247 (e) P=0.500 |P=0.344 P=0.309 P=0.753N P=0.309 |
|=================================================================================================================================|
Date: 02/24/00 EXPERIMENT: 88124 TEST: 04 Page 17
Statistical Analysis of Primary Tumors in Mice(B6C3F1) - INDIUM PHOSPHIDE
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.03 0.1MG/M3 0.3MG/M3 |CONTROL 0.03 0.1MG/M3 0.3MG/M3 |
| | MG/M3 STOP STOP | MG/M3 STOP STOP |
|=================================================================================================================================|
| |
|All Organs |
| Malignant Lymphoma: Histiocytic, Lymphocytic, Mixed, |
| NOS, or Undifferentiated Cell Type |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # |# # # # |
|----------- | | |
|OVERALL (a) | 1/50 (2%) 1/50 (2%) 3/50 (6%) 2/50 (4%) |8/50 (16%) 4/50 (8%) 10/50 (20%) 13/50 (26%) |
|POLY-3 ADJUSTED (b)| 2.2% 2.6% 7.0% 4.7% |17.0% 10.6% 20.9% 33.2% |
|TERMINAL (d) | 0/37 (0%) 1/24 (4%) 1/29 (3%) 0/27 (0%) |7/42 (17%) 1/13 (8%) 5/33 (15%) 7/21 (33%) |
|FIRST INCIDENCE | 686 733 (T) 657 562 |699 617 547 600 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.358 P=0.690 P=0.232 P=0.457 |P=0.005 ** P=0.458 P=0.265 P=0.006 ** |
|POLY 3 | P=0.386 P=0.722 P=0.276 P=0.470 |P=0.016 * P=0.299N P=0.413 P=0.066 |
|POLY 1.5 | P=0.393 P=0.737 P=0.288 P=0.482 |P=0.021 * P=0.237N P=0.412 P=0.098 |
|POLY 6 | P=0.373 P=0.706 P=0.262 P=0.454 |P=0.012 * P=0.404N P=0.403 P=0.039 * |
|LOGISTIC REGRESSION| P=0.409 P=0.730 P=0.320 P=0.711 |P=0.016 * P=0.362N P=0.392 P=0.033 * |
|COCH-ARM / FISHERS | P=0.399 P=0.753N P=0.309 P=0.500 |P=0.033 * P=0.178N P=0.398 P=0.163 |
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.03 0.1MG/M3 0.3MG/M3 |CONTROL 0.03 0.1MG/M3 0.3MG/M3 |
| | MG/M3 STOP STOP | MG/M3 STOP STOP |
|=================================================================================================================================|
| |
|All Organs |
| Benign Tumors |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # |# # # # |
|----------- | | |
|OVERALL (a) | 29/50 (58%) 27/50 (54%) 31/50 (62%) 35/50 (70%) |25/50 (50%) 24/50 (48%) 36/50 (72%) 26/50 (52%) |
|POLY-3 ADJUSTED (b)| 61.0% 65.2% 68.2% 76.4% |52.9% 59.6% 74.9% 61.7% |
|TERMINAL (d) | 24/37 (65%) 16/24 (67%) 22/29 (76%) 22/27 (82%) |23/42 (55%) 12/13 (92%) 25/33 (76%) 13/21 (62%) |
|FIRST INCIDENCE | 561 562 481 370 |664 514 617 496 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.016 * P=0.084 P=0.076 P=0.007 ** |P=0.033 * P<0.001 ** P<0.001 ** P=0.003 ** |
|POLY 3 | P=0.058 P=0.423 P=0.300 P=0.074 |P=0.285 P=0.337 P=0.018 * P=0.263 |
|POLY 1.5 | P=0.065 P=0.540 P=0.348 P=0.100 |P=0.343 P=0.494 P=0.019 * P=0.353 |
|POLY 6 | P=0.045 * P=0.326 P=0.246 P=0.049 * |P=0.222 P=0.140 P=0.016 * P=0.172 |
|LOGISTIC REGRESSION| P=0.035 * P=0.301 P=0.249 P=0.061 |P=0.167 P=0.084 P=0.012 * P=0.179 |
|COCH-ARM / FISHERS | P=0.069 P=0.420N P=0.419 P=0.149 |P=0.458 P=0.500N P=0.020 * P=0.500 |
|=================================================================================================================================|
Date: 02/24/00 EXPERIMENT: 88124 TEST: 04 Page 18
Statistical Analysis of Primary Tumors in Mice(B6C3F1) - INDIUM PHOSPHIDE
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.03 0.1MG/M3 0.3MG/M3 |CONTROL 0.03 0.1MG/M3 0.3MG/M3 |
| | MG/M3 STOP STOP | MG/M3 STOP STOP |
|=================================================================================================================================|
| |
|All Organs |
| Malignant Tumors |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # |# # # # |
|----------- | | |
|OVERALL (a) | 21/50 (42%) 35/50 (70%) 40/50 (80%) 30/50 (60%) |20/50 (40%) 25/50 (50%) 25/50 (50%) 27/50 (54%) |
|POLY-3 ADJUSTED (b)| 43.2% 72.9% 81.2% 63.0% |41.7% 58.8% 51.2% 62.6% |
|TERMINAL (d) | 11/37 (30%) 15/24 (63%) 20/29 (69%) 14/27 (52%) |15/42 (36%) 6/13 (46%) 14/33 (42%) 9/21 (43%) |
|FIRST INCIDENCE | 561 331 478 471 |626 489 547 512 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.168 P<0.001 ** P<0.001 ** P=0.014 * |P=0.021 * P<0.001 ** P=0.085 P<0.001 ** |
|POLY 3 | P=0.245 P=0.002 ** P<0.001 ** P=0.039 * |P=0.070 P=0.075 P=0.234 P=0.035 * |
|POLY 1.5 | P=0.260 P=0.002 ** P<0.001 ** P=0.043 * |P=0.094 P=0.127 P=0.233 P=0.055 |
|POLY 6 | P=0.233 P=0.002 ** P<0.001 ** P=0.035 * |P=0.054 P=0.031 * P=0.224 P=0.021 * |
|LOGISTIC REGRESSION| P=0.364 P=0.022 * P<0.001 ** P=0.111 |P=0.112 P=0.116 P=0.211 P=0.045 * |
|COCH-ARM / FISHERS | P=0.306 P=0.004 ** P<0.001 ** P=0.055 |P=0.160 P=0.211 P=0.211 P=0.115 |
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.03 0.1MG/M3 0.3MG/M3 |CONTROL 0.03 0.1MG/M3 0.3MG/M3 |
| | MG/M3 STOP STOP | MG/M3 STOP STOP |
|=================================================================================================================================|
| |
|All Organs |
| Malignant and Benign Tumors |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # |# # # # |
|----------- | | |
|OVERALL (a) | 41/50 (82%) 45/50 (90%) 46/50 (92%) 45/50 (90%) |35/50 (70%) 37/50 (74%) 45/50 (90%) 40/50 (80%) |
|POLY-3 ADJUSTED (b)| 83.7% 91.9% 93.4% 91.9% |73.0% 82.7% 90.0% 89.0% |
|TERMINAL (d) | 30/37 (81%) 21/24 (88%) 26/29 (90%) 24/27 (89%) |30/42 (71%) 13/13 (100%) 28/33 (85%) 18/21 (86%) |
|FIRST INCIDENCE | 561 331 478 370 |626 489 547 496 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.110 P=0.004 ** P=0.018 * P=0.013 * |P=0.004 ** P<0.001 ** P=0.002 ** P<0.001 ** |
|POLY 3 | P=0.246 P=0.169 P=0.112 P=0.170 |P=0.044 * P=0.180 P=0.025 * P=0.038 * |
|POLY 1.5 | P=0.254 P=0.178 P=0.109 P=0.178 |P=0.069 P=0.288 P=0.019 * P=0.069 |
|POLY 6 | P=0.241 P=0.161 P=0.125 P=0.164 |P=0.035 * P=0.068 P=0.032 * P=0.023 * |
|LOGISTIC REGRESSION| P=0.267 P=0.194 P=0.091 P=0.161 |P=0.038 * P=0.091 P=0.012 * P=0.013 * |
|COCH-ARM / FISHERS | P=0.270 P=0.194 P=0.117 P=0.194 |P=0.176 P=0.412 P=0.011 * P=0.178 |
|=================================================================================================================================|
(a) Number of tumor-bearing animals / number of animals examined at site.
(b) Poly-3 adjusted lifetime tumor incidence.
(d) Observed incidence at terminal kill.
(f) Beneath the control incidence are the P-values associated with the trend
test. Beneath the dosed group incidence are the P-values corresponding to
pairwise comparisons between the controls and that dosed group. The life
table analysis regards tumors in animals dying prior to terminal kill as
being (directly or indirectly) the cause of death.
Logistic regression is an alternative
method for analyzing the incidence of non-fatal tumors. The Cochran-Armitage
and Fishers exact tests compare directly the overall incidence rates
For all tests a negative trend is indicated by N
(e) Value of Statistic cannot be computed.
(I) Interim sacrifice
(T) Terminal sacrifice
# Tumor rates based on number of animals necropsied.
* To the right of any statistical result, indicates significance at (P<=0.05).
** To the right of any statistical result, indicates significance at (P<=0.01).
--multipart-boundary
Content-type: text/plain
Range: bytes 145978-145978/145978
--multipart-boundary--